first-in-class, bioavailable BCL-XL inhibitor
oral efficacy in xenograft, led to ADC dev.
from SBDD of prior BH3 mimetics
ACS Med. Chem. Lett., Jul. 5, 2020
AbbVie, North Chicago, IL / Genentech
A-1331852 is a highly potent, orally bioavailable inhibitor of BCL-XL, blocking a protein-protein interaction resulting in tumor cell apoptosis. The compound was an important tool compound for understanding the…